Skip to content
value.today

Autolus Therapeutics

6A3A.F
$641 Mmarket cap on Aug 1, 2026-45.2% since Jan 2024
Compare
World rank
#11,490
Revenue
$75 M
For year ending December-2025
Net income
$-288 M
-381.4% margin
SEC filing
Employees
—

Autolus Therapeutics in brief

Autolus Therapeutics is a listed company in the Biotechnology industry, based in London, UK. Its market value was $641 M on 1 August 2026, which makes it the 11,490th largest listed company in the world and the 361st largest in the UK on this site. In the year to December 2025 it had sales of $75 M and a net loss of $288 M. Its largest product and service lines by sales in 2025 were License (1%). Its shares trade under the symbol 6A3A.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Autolus Therapeutics

Autolus Therapeutics is a Biopharmaceutical company. The headquarters is in UK.

Autolus Therapeutics timeline

1 events, 2018
  1. 2018
  2. 🔔
    · approximate
    Initial public offering on Frankfurt

Events of Autolus Therapeutics from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$316 M$632 M$948 M$1.3 B2020202120222023202420252026

World rank over time

▼ down 2,006 places since 2020
2020-01-01: #9257#9,25720202021-01-01: #10526#10,52620212022-01-07: #15847#15,84720222022-12-25: #18558#18,55820222023-07-30: #12972#12,97220232024-01-05: #7826#7,82620242026-08-01: #11263#11,2632026

Rank in UK: #314 (Jan 2020) · #499 (Jan 2021) · #668 (Jan 2022) · #689 (Dec 2022) · #474 (Jul 2023) · #284 (Jan 2024) · #363 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.7×
Price / book
3.6×
Free cash flow yield
-47.2%
Net margin (TTM)
-186.3%
Operating margin
-358.9%
Return on equity
-143.8%
Liabilities / assets
69.8%
Net debt
$-211M
Revenue growth
+645.0%
R&D / revenue
156.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $1M, net income $-45M$1MFY18Fiscal year ending Dec 2019: revenue $3M, net income $-124M$3MFY19Fiscal year ending Dec 2020: revenue —, net income $-142M—FY20Fiscal year ending Dec 2021: revenue —, net income $-142M—FY21Fiscal year ending Dec 2022: revenue —, net income $-149M—FY22Fiscal year ending Dec 2023: revenue $2M, net income $-208M$2MFY23Fiscal year ending Dec 2024: revenue $10M, net income $-221M$10MFY24Fiscal year ending Dec 2025: revenue $75M, net income $-288M$75MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$75M+645.0%$-271M$-288M-381.4%
Dec 2024$10M+495.3%$-241M$-221M-2180.4%
Dec 2023$2M—$-180M$-208M-12257.6%
Dec 2022——$-143M$-149M—
Dec 2021——$-141M$-142M—
Dec 2020——$-168M$-142M—
Dec 2019$3M+106.4%$-146M$-124M-4256.0%
Sep 2018$1M—$-58M$-45M-3173.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-284M$19M$-303M$-1.08—
Dec 2024$-206M$22M$-228M$-0.86—
Dec 2023$-146M$11M$-157M$-1.20—
Dec 2022$-112M$11M$-123M$-1.57—
Dec 2021$-118M$9M$-127M$-1.97—
Dec 2020$-118M$15M$-132M$-2.76—
Dec 2019$-101M$18M$-120M$-2.88—
Sep 2018$-32M$9M$-41M$-1.42—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$137M
Net income, trailing 12 months
$-256M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-28M—Dec ’24Three months to Mar 2025: revenue $9M, net income $-70M$9MMar ’25Three months to Jun 2025: revenue $21M, net income $-48M$21MJun ’25Three months to Sep 2025: revenue $21M, net income $-79M$21MSep ’25Three months to Dec 2025 (from the annual report): revenue $24M, net income $-90M$24MDec ’25Three months to Mar 2026: revenue $26M, net income $-72M$26MMar ’26Three months to Jun 2026: revenue $46M, net income $-39M$46MJun ’26Three months to Sep 2026: revenue $41M, net income $-55M$41MSep ’26

Latest quarter to Sep 2026: revenue $41M (+94.6% on a year earlier), net income $-55M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Autolus Therapeutics with the US Securities and Exchange Commission.

Annual results

Revenue
$75 M
Operating income
$-271 M
Net income
$-288 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$589 M
Total liabilities
$411 M
Total equity
$178 M

As of December-2025

Top 91 institutional investors in Autolus Therapeutics#

As of Sep 30, 2026
91 institutions held 131.3 M shares (about 37.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 31.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Autolus Therapeutics
#InstitutionShares heldChange (shares)% heldValueFiled
1Mak Capital One LLC30,528,859-3,092,628 (-9.20%)8.66%$59 MNov 16, 2026
2Blackstone Inc.20,485,6110 (0.00%)5.81%$40 MNov 16, 2026
3Syncona Portfolio Ltd16,640,7200 (0.00%)4.72%$32 MNov 5, 2026
4Armistice Capital, LLC13,750,000-1,250,000 (-8.33%)3.90%$27 MNov 16, 2026
5Tetragon Partners GP Ltd9,500,0000 (0.00%)2.70%$18 MNov 16, 2026
6Schroder Investment Management Group6,130,793-1,702,489 (-21.73%)1.74%$12 MNov 16, 2026
7Frazier Life Sciences Management, L.P.4,447,9100 (0.00%)1.26%$9 MNov 16, 2026
8BNP PARIBAS ASSET MANAGEMENT Holding S.A.3,361,1560 (0.00%)0.95%$7 MNov 13, 2026
9Laurion Capital Management LP3,316,6260 (0.00%)0.94%$6 MOct 30, 2026
10Renaissance Technologies LLC2,492,900+508,200 (+25.61%)0.71%$5 MNov 12, 2026
11Millennium Management LLC2,164,182+939,364 (+76.69%)0.61%$4 MNov 16, 2026
12Morgan Stanley2,105,535+844,703 (+67.00%)0.60%$4 MNov 13, 2026
13Citadel Advisors LLC1,630,469+934,579 (+134.30%)0.46%$3 MNov 16, 2026
14BlackRock, Inc.1,510,455-93,003 (-5.80%)0.43%$3 MNov 13, 2026
15UBS Group AG1,429,205-87,786 (-5.79%)0.41%$3 MNov 10, 2026
16Cetera Investment Advisers1,235,300+77,976 (+6.74%)0.35%$2 MNov 13, 2026
17Walleye Capital LLC1,214,501New0.34%$2 MNov 13, 2026
18Bank Of America Corp /de/1,002,832-602,260 (-37.52%)0.28%$2 MNov 16, 2026
19Goldman Sachs Group Inc972,969+859,413 (+756.82%)0.28%$2 MNov 16, 2026
20Jpmorgan Chase & Co897,639-15,600 (-1.71%)0.25%$2 MNov 12, 2026
21UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC717,623New0.20%$1 MNov 16, 2026
22Privium Fund Management B.V.469,490+106,060 (+29.18%)0.13%$1 MNov 3, 2026
23Hennion & Walsh Asset Management, Inc.419,217-32,186 (-7.13%)0.12%$1 MOct 13, 2026
24EDENTREE ASSET MANAGEMENT Ltd300,0000 (0.00%)0.09%$1 MNov 16, 2026
25Acadian Asset Management LLC286,711+258,582 (+919.27%)0.08%$1 MNov 9, 2026
Show all 91: investors 26 to 91
Institutional investors 26 to 91 in Autolus Therapeutics
#InstitutionShares heldChange (shares)% heldValueFiled
26Tidal Investments LLC273,617New0.08%$1 MNov 13, 2026
27Aquatic Capital Management LLC261,360New0.07%$1 MNov 16, 2026
28Qube Research & Technologies Ltd261,082New0.07%$1 MNov 13, 2026
29Quadrature Capital Ltd224,193+109,310 (+95.15%)0.06%$0 MNov 13, 2026
30Jane Street Group, LLC212,313-87,549 (-29.20%)0.06%$0 MNov 12, 2026
31Wells Fargo & Company/mn210,922-1,670 (-0.79%)0.06%$0 MNov 16, 2026
32Erste Asset Management GmbH195,0000 (0.00%)0.06%$0 MNov 12, 2026
33DAFNA Capital Management LLC179,3160 (0.00%)0.05%$0 MNov 16, 2026
34HRT Financial LP164,950+75,587 (+84.58%)0.05%$0 MNov 13, 2026
35Voleon Capital Management LP156,250New0.04%$0 MNov 16, 2026
36Nano Cap New Millennium Growth Fund L P150,0000 (0.00%)0.04%$0 MNov 13, 2026
37Point72 Asset Management, L.P.134,420+63,193 (+88.72%)0.04%$0 MNov 16, 2026
38Susquehanna International Group, LLP132,727-44,505 (-25.11%)0.04%$0 MNov 16, 2026
39Graham Capital Management, L.P.122,726New0.03%$0 MNov 16, 2026
40Clearstead Advisors, LLC121,1070 (0.00%)0.03%$0 MNov 6, 2026
41Two Sigma Investments, LP106,889New0.03%$0 MNov 16, 2026
42State Street Corp101,955+17,546 (+20.79%)0.03%$0 MNov 12, 2026
43Engineers Gate Manager LP100,307New0.03%$0 MNov 16, 2026
44Leonteq Securities AG100,0000 (0.00%)0.03%$0 MOct 29, 2026
45Aigen Investment Management, LP82,392+64,555 (+361.92%)0.02%$0 MNov 16, 2026
46Axq Capital, LP77,197New0.02%$0 MNov 12, 2026
47Invesco Ltd.64,921-1,526 (-2.30%)0.02%$0 MNov 12, 2026
48XTX Topco Ltd57,434-230,022 (-80.02%)0.02%$0 MNov 16, 2026
49SmartHarvest Portfolios, LLC48,639-14,963 (-23.53%)0.01%$0 MOct 26, 2026
50WINTON GROUP Ltd48,000New0.01%$0 MNov 12, 2026
51LPL Financial LLC42,745+120 (+0.28%)0.01%$0 MNov 6, 2026
52Squarepoint Ops LLC38,693New0.01%$0 MNov 9, 2026
53HighPoint Advisor Group LLC37,000-20,000 (-35.09%)0.01%$0 MNov 9, 2026
54China Universal Asset Management Co., Ltd.36,602+4,677 (+14.65%)0.01%$0 MOct 28, 2026
55Blair William & Co/il36,500+21,500 (+143.33%)0.01%$0 MNov 10, 2026
56Rhumbline Advisers36,295-2,469 (-6.37%)0.01%$0 MNov 10, 2026
57Virtu Financial LLC33,057+9,500 (+40.33%)0.01%$0 MNov 17, 2026
58R Squared Ltd31,360-5,066 (-13.91%)0.01%$0 MNov 6, 2026
59Rathbones Group PLC28,0500 (0.00%)0.01%$0 MNov 12, 2026
60Osaic Holdings, Inc.27,7240 (0.00%)0.01%$0 MNov 12, 2026
61Waverly Advisors, LLC26,8700 (0.00%)0.01%$0 MNov 16, 2026
62Caitong International Asset Management Co., Ltd26,145+9,944 (+61.38%)0.01%$0 MOct 29, 2026
63Manufacturers Life Insurance Company, The25,851+659 (+2.62%)0.01%$0 MNov 13, 2026
64Delaney Dennis R24,0000 (0.00%)0.01%$0 MNov 13, 2026
65Barclays PLC18,953+7,014 (+58.75%)0.01%$0 MNov 6, 2026
66Vise Technologies, Inc.18,084New0.01%$0 MOct 29, 2026
67Marex Group Ltd17,8570 (0.00%)0.01%$0 MNov 16, 2026
68GAMMA Investing LLC16,425+926 (+5.97%)0.00%$0 MOct 8, 2026
69SIH Partners, LLLP16,254+1,367 (+9.18%)0.00%$0 MNov 16, 2026
70Lido Advisors, LLC16,036+527 (+3.40%)0.00%$0 MNov 4, 2026
71Private Advisor Group, LLC14,220New0.00%$0 MNov 10, 2026
72Apollon Wealth Management, LLC14,003-16 (-0.11%)0.00%$0 MOct 23, 2026
73Geode Capital Management, LLC13,356-110,578 (-89.22%)0.00%$0 MNov 6, 2026
74Dumont & Blake Investment Advisors LLC13,000-1,000 (-7.14%)0.00%$0 MOct 28, 2026
75Vanguard Personalized Indexing Management, LLC12,743-4,217 (-24.86%)0.00%$0 MNov 16, 2026
76Claro Advisors Inc.12,5000 (0.00%)0.00%$0 MNov 2, 2026
77Simplicity Wealth,LLC10,838New0.00%$0 MOct 23, 2026
78Independent Advisor Alliance10,650-11,692 (-52.33%)0.00%$0 MNov 10, 2026
79Mirae Asset Global Investments Co., Ltd.10,251+1,280 (+14.27%)0.00%$0 MOct 29, 2026
80Meridian Financial Partners LLC10,000New0.00%$0 MOct 23, 2026
81Wealth Effects LLC10,0000 (0.00%)0.00%$0 MOct 23, 2026
82BNP Paribas Financial Markets7,582+700 (+10.17%)0.00%$0 MNov 12, 2026
83Tower Research Capital LLC (TRC)6,528-1,005 (-13.34%)0.00%$0 MNov 16, 2026
84TrinityBridge Ltd6,3000 (0.00%)0.00%$0 MOct 30, 2026
85Citigroup Inc5,331+613 (+12.99%)0.00%$0 MNov 4, 2026
86GF Fund Management Co. LTD.4,523+369 (+8.88%)0.00%$0 MOct 26, 2026
87Pinnacle Financial Group, Inc.1,000—0.00%$0 MNov 16, 2026
88Caldwell Sutter Capital, Inc.5000 (0.00%)0.00%$0 MNov 9, 2026
89Byrne Asset Management LLC1000 (0.00%)0.00%$0 MOct 6, 2026
90SBI Securities Co., Ltd.55+1 (+1.85%)0.00%$0 MOct 22, 2026
91Allworth Financial LP500 (0.00%)0.00%$0 MNov 17, 2026

Mutual funds holding Autolus Therapeutics#

4 funds hold shares worth $3 M. Since their previous reports 4 added shares and 4 sold, selling $1 M net.
Mutual funds holding Autolus Therapeutics
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.43 M$2 M—0.03%+8.1%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC120,878$0 M—<0.01%+9.3%May 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.84,409$0 M—0.02%+1.0%Jun 30, 2026
🇺🇸 ActivePassive International Equity ETFTrust for Professional Managers22,753$0 M—<0.01%newMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Autolus Therapeutics#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$16 K
1 sale, 1 insider
Net, 12 months
-$16 K
open market only
Insiders on file
1
since
Autolus Therapeutics: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Cintia PiccinaU.S. CCO & Country Gen ManagerSell-6,713$2.340$16 K13,287Form 4
filed Cintia PiccinaU.S. CCO & Country Gen ManagerOption exercise+20,000$2.350$47 K20,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Autolus Therapeutics#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
8.6 M
4.73 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 2,210 shares at $1.60
  • : 620 shares at $1.86
  • : 5,757 shares at $1.95
  • : 56 shares at $2.29
  • : 58 shares at $2.31

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Autolus Therapeutics scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 3
    • ✓Revenue grew in the newest year645.0%Revenue up 645.0% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.08 vs -0.86Diluted EPS -1.08 in fiscal 2025 against -0.86 the year before (report's currency).
    • ✗Net income higher than five years earlier-$288 M-$288 M in fiscal 2025 against -$142 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$288 MNet income -$288 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-358.9%-358.9% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-95.0%-95.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities5.9×Current ratio 5.94 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-7.4×Operating income -7.4 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.01Z-score -3.01 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.3%Diluted shares up 4.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Autolus Therapeutics's statements, beside the median of Biotechnology.

Autolus Therapeutics: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-358.9%-60.5%
Net margin-381.4%-68.9%
Return on equity-95.0%-61.0%
Revenue growth645.0%15.8%
Free cash flow margin-401.4%-61.5%

2of 8on the Piotroski tests of financial strength

  • Net loss of $288 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$303 million.
  • Operating income covers the interest bill only -7.4 times.

Autolus Therapeutics: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Autolus Therapeutics: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue75101.7———2.91.41.71.2
Cost of revenue96110———————
Research and development118138130117r111r135105361610
Selling, general and administrative132102r47———————
General and administrative——4732323539239.15.2
Operating expenses———————582314
Operating income−271−241−180−143r−141r−168−146−58−23—
Interest and finance income1932141.70.30.52.51.50.10.1
Interest expense and finance costs379.3458.91.100———
Other non-operating income (expense)−1522−29−5.2−1.01.97.15.50.00.0
Income before tax−286−219−208−149r−142r−166−139−52−23−14
Income tax2.01.5−0.0r0.3r0.1r−24−15−7.3−3.7−1.8
Net income attributable to shareholders−288−221−208−149−142−142−124−45−20−13
Earnings per share, basic-1.08-0.86-1.20-1.57-1.97-2.76-2.88-1.42-1.43-1.26
Earnings per share, diluted-1.08-0.86-1.20-1.57-1.97-2.76-2.88-1.42-1.43-1.26
Shares, weighted average (basic)26625517495725243———
Shares, weighted average (diluted)2662551749572524332149.9
Balance sheet
Cash and cash equivalents104227240382310r153211247r13728
Short-term investments1973610———————
Receivables240.00.10.10—————
Inventory334.10———————
Other current assets01.6r0r0.20.200.30.70—
Current assets436661275426347197249259142—
Property, plant and equipment64503535343828146.2—
Right-of-use (leased) assets65556123195223———
Other intangible assets2012000.10.20.30.40—
Total assets589783375490406294304273149—
Accounts payable3.12.00.10.50.42.31.13.01.9—
Current liabilities73614546293425175.0—
Long-term debt——————00.40.8—
Lease liabilities (non-current)67504819175124———
Total liabilities411355264192928449186.1—
Retained earnings−1,387−1,099−879−670−521−379−237−93−48—
Shareholders' equity17842711129931321025525514331
Total liabilities and equity589783375490406294304273149—
Cash-flow statement
Depreciation and amortization8.37.66.67.48.55.74.6———
Share-based compensation141511r129.920306.83.22.3
Cash from operating activities−284−206−146−112−118−118−101−32−16−9.8
Capital expenditure−19−22−11−11−8.9−15−18−9.1−2.9−1.9
Intangible assets bought−8.1−130—00−0.3−0.400
Cash from investing activities158−395−11−11−8.9−15−19−9.5−2.9−1.9
Shares issued0550016424680r116r15712832
Cash from financing activities−4.3590−0.92242847410915712832
Exchange-rate effect on cash6.3−0.315−28−0.80.75.2−5.80.6−2.7
Change in cash−123−12−14272157−57−6.111010918
Report10-K10-K10-K10-K10-K20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Autolus Therapeutics sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product revenue, net(total)$74 M99%
  • License$1 M1.5%

Business segments

  • Reportable$75 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Autolus Therapeutics operates: 4 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.

Autolus Therapeutics: countries of operation
CountryPresenceRevenue there
🇬🇧 UKHeadquarters2 subsidiaries—
🇩🇪 Germany1 subsidiary—
🇨🇭 Switzerland1 subsidiary—
🇺🇸 USA1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Autolus Therapeutics#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Restructuring 1 · Directors and officers 4 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 9

Autolus Therapeutics: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Restructuring8-K
Auditor changed8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Directors and officersResults announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Discuss Autolus Therapeutics#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 10 November 2026automatic update · Nov 10, 2026

    Autolus Therapeutics announced results on 10 November 2026 (SEC Form 8-K, item 2.02).

  • Mutual funds: 4 funds hold $3 millionautomatic update · Jun 30, 2026

    4 mutual funds in 1 country hold shares of Autolus Therapeutics worth $3 million (funds' newest reports, up to 30 June 2026). Since their previous reports 4 funds added shares and 4 sold; on balance they sold $1 million. Share splits are not counted as trading.

How Autolus Therapeutics compares in Biotechnology

  • Market cap$641 M · higher than 61% of 726
  • Revenue$75 M · higher than 66% of 647
  • Net margin-186.3% · higher than 30% of 408
  • Revenue growth645.0% · higher than 96% of 438
  • Price / sales4.7× · lower than 64% of 339
  • Price / book3.6× · lower than 41% of 534
  • FCF yield-47.2% · higher than 25% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Autolus Therapeutics🇬🇧$641 M—-186.3%+645.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Autolus Therapeutics? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Autolus Therapeutics's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Autolus Therapeutics? Suggest a correction